SAM
ALLO icon

Sagewood Asset Management’s Allogene Therapeutics ALLO Stock Holding History

Sagewood Asset Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,625
Closed -$22.8K – 343
2025
Q4 		$22.8K Buy
+16,625
New +$21.9K 0.01% 254

Other funds holding ALLO

P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sagewood Asset Management's ALLO Position: Q1 2026 in Review

Sagewood Asset Management sold out of Allogene Therapeutics (ALLO) in Q1 2026, closing a stake of 16,625 shares — an estimated $22.8K sold.

Sagewood Asset Management first reported a position in ALLO in Q4 2025 and held it in 1 quarter. The position peaked at $22.8K in Q4 2025. 209 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Sagewood Asset Management reported no remaining Allogene Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Sagewood Asset Management sold 16,625 Allogene Therapeutics shares in Q1 2026, an estimated $22.8K.
  • Sagewood Asset Management first reported a position in Allogene Therapeutics in Q4 2025 and held it in 1 quarter.
  • Sagewood Asset Management's Allogene Therapeutics position peaked at $22.8K in Q4 2025.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Sagewood Asset Management's 13F filing for Q1 2026, filed 13 May 2026.